Ixazomib manufacturers

Filters

ixazomib

Capsules 2.3 mg, 3 mg, 4 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
FDA, EU GMP
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

ixazomib

Capsules 2.3 mg, 3 mg, 4 mg

Dossier type
US CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
FDA, EU GMP
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

ixazomib

Capsules 2.3 mg, 3 mg, 4 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
EU GMP
Manufacturer #34185

Established in 1994, this innovative R&D and manufacturing company focuses on the pharmaceutical and health sectors. As a CTD dossier owner and manufacturer, it ensures compliance with international quality standards, operating sophisticated drug production facilities that meet cGMP specifications from regulatory bodies such as NMPA, FDA, and EMA. The company's diverse portfolio includes biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs), with over 300 product approvals across various categories. Its products are distributed in more than 40 countries and regions, including Singapore, South Korea, Italy, and China.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.